Mega Lifesciences Public Co. Ltd. · SET:MEGA
Mega Lifesciences Public — American Diabetes Association (ADA) 84th Scientific Sessions 2024
20 slides from Mega Lifesciences Public's conference presentation, July 2024
Slide 1: American Diabetes Association (ADA) 84th Scientific Sessions
American Diabetes Association (ADA) 84" Scientific Sessions | JUNE 21-24, 2024 | | ORLANDO |
Slide 2: Contents
* Contents © Normal and Diabetes Patients’ Foot Neuro Activity comparison 1 © Insparin, a New Class of Antidiabetes Agent as per preclinical study data 2 © Prediabetes Remission mechanisms in People with Weight Gain after Lifestyle Intervention 3 © Effectiveness of Carbohydrate-Restricted Nutrition
Slide 3: Normal and Diabetes Patients' Foot Neuro Activity comparison
Normal and Diabetes Patients’ Foot Neuro Activity comparison Kim W, Park MS. Diabetes. 2024 Jun 14;73(Supplement_1). t Background and Objective: > Nanofilament test or sending a weak electric shock to the patient is one simple diagnostic method to determine foot insensitivity. > Accuracy of this tes
Slide 4: Insparin, a New Class of Antidiabetes Agent
Insparin, a New Class of Antidiabetes Agent as per preclinical study data Dhurandhar N, Hegde V. Diabetes. 2024 Jun 14;73(Supplement_1). t_Introduction and Objectives: > Improvement in glycemic control was observed in mice with human adenovirus-36 (Ad36) infection via its product E4orf1 gene (termed
Slide 5: Prediabetes Remission mechanisms in People with Weight Gain after Lifestyle Intervention
Prediabetes Remission mechanisms in People with Weight Gain after Lifestyle Intervention Sandforth A, Vazquez Arreola EL, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢ Background and Objective: > It is shown that during lifestyle intervention (LI) weight loss-induced prediabetes remission is dete
Slide 6: Effectiveness of Carbohydrate-Restricted Nutrition Therapy in Adults with Prediabetes
ee Effectiveness of Carbohydrate-Restricted Nutrition Therapy in Adults with Prediabetes - One Year Real-World Evidence Roberts CG, Adams RN, et al. Diabetes. 2024 Jun 14;73(Supplement_1). + Background and Objective: > 38% of US adults are affected by prediabetes (preD) with a growing presence among
Slide 7: Relationships among Food Addiction and Glycemic Control in Type 2 Diabetes
ee Relationships among Food Addiction and Glycemic Control in Patients with Type 2 Diabetes Mellitus and Healthy Controls Smeltzer JT, Kumar R, et al. Diabetes. 2024 Jun 14;73(Supplement_1). :_Introduction and Objective: > Poor glycemic control and health outcomes in type 2 diabetes (T2DM) were rela
Slide 8: 2 years comparative efficacy results for use of Semaglutide in Type 2 Diabetes
2 years comparative efficacy results for use of Semaglutide in Type 2 Diabetes - Randomized Pragmatic Clinical Trial Buse JB, Soule BP, et al. Diabetes. 2024 Jun 14;73(Supplement_1). t Objective: > The study aims to generate real-world evidence to support clinical decision-making by evaluating the l
Slide 9: Oral Antidiabetic Drugs Added to Short-Term Continuous Subcutaneous Insulin Infusion
In patients with Type 2 Diabetes, efficacy and safety of Oral Antidiabetic Drugs Added to Short-Term continuous subcutaneous insulin infusion Jiang W, Chen D, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢ Background and Objective: > Intype 2 diabetes (T2D) patients, Short-term continuous subcutan
Slide 10: Real world data on Improved Glycemic Control with IDegAsp
Real world data on Improved Glycemic Control in People with Type 2 Diabetes (T2D) Initiating or Switching to Insulin Degludec/Insulin Aspart (IDegAsp) Guo L, Chen L, et al. Diabetes. 2024 Jun 14;73(Supplement_1). t_ Objective: This study aims to investigate clinical parameters of T2D patients treate
Slide 11: Intensification of Human Insulin Therapy with SGLT2 Inhibitors
In Type 2 Diabetes Mellitus patients, results for Intensification of Human Insulin Therapy with SGLT2 Inhibitors Dzida GJ, Gajda P, et al. 2024 Jun 14;73(Supplement_1). ¢ Background and Objective: > Type 2 diabetes mellitus (T2DM) guidelines and registered indications recommend treatment intensifica
Slide 12: Treatment satisfaction improvements with Gla-300 in Insulin-Naive people with T2D
Treatment satisfaction improvements with Gla-300 in Insulin-Naive people with T2D - Real-World ATOS PRO post-hoc Study Harris SB, Khan N, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢_ Background and Objective: > Randomized control trials and real-world studies have shown initiating Gla-300 impro
Slide 13: Fixed-Dose Combination of Atorvastatin/Fenofibrate for Residual Lipid Risk
ee Fixed-Dose Combination of Atorvastatin/Fenofibrate treatment for reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Sander-padilla JG, Lugo-sdnchez LA, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢_ Introduction and Objective: » Residual cardiovascular ris
Slide 14: Cardiovascular outcomes of SGLT2i vs DPP4i: Systematic Review and Meta-analysis
Cardiovascular outcomes of initiator therapy with Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Dipeptidy! Peptidase 4 Inhibitor (DPP4i) in Type 2 Diabetes on - A Systematic Review and Meta-analysis Shrestha AB, Rajak K, et al. Diabetes. 2024 Jun 14;73(Supplement_1). :_ Introduction and Obj
Slide 15: Glycemic Variability after Initiation of SGLT2 Inhibitors in CKD
Glycemic Variability after Initiation of SGLT2 Inhibitors in CKD Tang M, De boer IA, et al. Diabetes. 2024 Jun 14;73(Supplement_1). t_ Background: > SGLT2 inhibitors (SGLT2i) are widely used for cardiorenal protection in CKD patients, irrespective of diabetes. > Study aims to evaluate the impact of
Slide 16: Prescription Pattern of SGLT-2 Inhibitors among Seniors with T2DM and CKD
Prescription Pattern of SGLT-2 Inhibitors among Seniors with Type 2 Diabetes Mellitus and Chronic Kidney Disease in a Primary Care Setting Naous E, Elnajjar M, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢_ Background and Objective: > SGLT-2 inhibitors (SGLT2i) remain under-prescribed in eligible
Slide 17: Use of GLP-1 Agonists and Perioperative Complications in Elective Surgery
ee Use of GLP-1 Agonists and Perioperative Complications in Patients Undergoing Elective Surgery Mendez CE, Thorgerson A, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢_ Introduction and Objective: > Apreoperative diabetes optimization program (PreDOP) is availabe for elective surgical patients wi
Slide 18: Impact of delay in statin therapy due to statin nonacceptance
In Patients with Diabetes, impact of delay in statin therapy due to statin nonacceptance on cardiovascular outcomes Shah N, Lan Z, et al. Diabetes. 2024 Jun 14;73(Supplement_1). ¢_ Background and Objective: > Many patients with diabetes do not accept their clinicians’ statin therapy recommendations.
Slide 19: LENS Trial - The Effect of Fenofibrate on Progression of Diabetic Retinopathy
LENS Trial - The Effect of Fenofibrate on Progression of Diabetic Retinopathy Preiss D, Logue J, et al. NEJM Evidence. 2024 Jun 21:EVIDoa2400179. ¢_ Background and Objective: > Diabetic retinopathy is aleading cause of visual loss globally, with increasing prevalence in many regions of the world ove
Slide 20: Panfor SR =PERGLIM PeRGuMM Gly4par
"4 ) 6 ( ~ Panfor SR =PERGLIM PeRGuMM Gly4par "Release Tablets S00m/1000mg Glimepiride Tablets 1mg/2mg/3mg/4mg Gimepide and WetonminHycoctloride SR Tales lene teed ease tles30 nang XX / J X J X / ‘a ~ (~ ~ ( ~ f ~ INSUNOVA- 29/70 (sipnecie INSUNOVA-N INSUNOVA-R Insunova-G Insulin Ijecton, Biphasic I
Mega Lifesciences Public — American Diabetes Association (ADA) 84th Scientific Sessions 2024 on 6ix